New frontiers in nanotechnology for cancer treatment.

[1]  S. Dübel,et al.  Antibody Engineering , 2010, Springer Berlin Heidelberg.

[2]  Robert Langer,et al.  Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. , 2007, Biomaterials.

[3]  S. Gopinath.  Methods developed for SELEX , 2006, Analytical and bioanalytical chemistry.

[4]  A. Verkleij,et al.  Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies , 2007, Cancer Immunology, Immunotherapy.

[5]  Robert Langer,et al.  An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. , 2006, Angewandte Chemie.

[6]  R. Langer,et al.  Nanomedicine: developing smarter therapeutic and diagnostic modalities. , 2006, Advanced drug delivery reviews.

[7]  T. Witzig.  Radioimmunotherapy for B-cell non-Hodgkin lymphoma. , 2006, Best practice & research. Clinical haematology.

[8]  F. Szoka,et al.  A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas , 2006, Proceedings of the National Academy of Sciences.

[9]  S Moein Moghimi,et al.  Recent developments in polymeric nanoparticle engineering and their applications in experimental and clinical oncology. , 2006, Anti-cancer agents in medicinal chemistry.

[10]  Hua Ai,et al.  Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. , 2006, Nano letters.

[11]  K. Strebhardt,et al.  Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. , 2006, Biomaterials.

[12]  Ralph Weissleder,et al.  In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. , 2006, Neoplasia.

[13]  D. Shangguan,et al.  Aptamers evolved from live cells as effective molecular probes for cancer study , 2006, Proceedings of the National Academy of Sciences.

[14]  Leonard G Presta,et al.  Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. , 2006, Advanced drug delivery reviews.

[15]  Donald L Weaver,et al.  Selection of tumor-binding ligands in cancer patients with phage display libraries. , 2006, Cancer research.

[16]  M J Hawkins,et al.  Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Á. Delgado,et al.  Preparation and characterization of carbonyl iron/poly(butylcyanoacrylate) core/shell nanoparticles. , 2006, Journal of colloid and interface science.

[18]  R. Cristiano,et al.  PEGylated J591 mAb loaded in PLGA-PEG-PLGA tri-block copolymer for targeted delivery: in vitro evaluation in human prostate cancer cells. , 2006, International journal of pharmaceutics.

[19]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[20]  D. Goldenberg,et al.  Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates , 2006, CA: a cancer journal for clinicians.

[21]  Yong Wang,et al.  Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras , 2006, Nature Biotechnology.

[22]  Andrew D Ellington,et al.  Aptamer:toxin conjugates that specifically target prostate tumor cells. , 2006, Cancer research.

[23]  G. Marcucci,et al.  Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[24]  Ralph Weissleder,et al.  In Vivo Phage Display Selection Yields Atherosclerotic Plaque Targeted Peptides for Imaging , 2006, Molecular Imaging and Biology.

[25]  N. Goldstein,et al.  Identification of cancer targets and therapeutics using phage display. , 2006, Current opinion in drug discovery & development.

[26]  R. Cristiano,et al.  Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate , 2006, Gene Therapy.

[27]  D. Furman,et al.  Tumorigenesis and Neoplastic Progression Galectin-3 Expression Correlates with Apoptosis of Tumor-Associated Lymphocytes in Human Melanoma Biopsies , 2006 .

[28]  Robert Langer,et al.  Nanoparticle–aptamer bioconjugates for cancer targeting , 2006, Expert opinion on drug delivery.

[29]  Allan S Hoffman,et al.  Poly(N-isopropylacrylamide-co-propylacrylic acid) copolymers that respond sharply to temperature and pH. , 2006, Biomacromolecules.

[30]  J. Richie,et al.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[31]  H. Shmeeda,et al.  Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors , 2006, Molecular Cancer Therapeutics.

[32]  T. Muramatsu,et al.  Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug. , 2006, Japanese journal of clinical oncology.

[33]  U. Wetterauer,et al.  A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells , 2006, Cancer Immunology, Immunotherapy.

[34]  T. Witzig,et al.  Radioimmunotherapy for B-cell non-Hodgkin lymphoma. , 2006, Clinical advances in hematology & oncology : H&O.

[35]  David C. Smith,et al.  Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. , 2006, Clinical genitourinary cancer.

[36]  Umesh Gupta,et al.  Dendrimers: novel polymeric nanoarchitectures for solubility enhancement. , 2006, Biomacromolecules.

[37]  David Schrama,et al.  Antibody targeted drugs as cancer therapeutics , 2006, Nature Reviews Drug Discovery.

[38]  Cuisong Zhou,et al.  Detection of oncoprotein platelet-derived growth factor using a fluorescent signaling complex of an aptamer and TOTO , 2006, Analytical and bioanalytical chemistry.

[39]  A. Saven,et al.  Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Thommey P. Thomas,et al.  PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. , 2006, Biomacromolecules.

[41]  A. Chilkoti,et al.  Structural optimization of a "smart" doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[42]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[43]  F. M. Huennekens,et al.  Methotrexate-a-Phenylalanine: Optimization of Methotrexate Prodrug for Activation by Carboxypeptidase A-Monoclonal Antibody Conjugate1 , 2006 .

[44]  A. Mikos,et al.  Biodegradable polymeric scaffolds. Improvements in bone tissue engineering through controlled drug delivery. , 2006, Advances in biochemical engineering/biotechnology.

[45]  A. Mamalaki,et al.  Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment , 2006, Cancer Immunology, Immunotherapy.

[46]  You Han Bae,et al.  Polymer Architecture and Drug Delivery , 2006, Pharmaceutical Research.

[47]  U. Gatzemeier,et al.  [EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer]. , 2005, Medizinische Klinik.

[48]  Francis C Szoka,et al.  Designing dendrimers for biological applications , 2005, Nature Biotechnology.

[49]  W. Stemmer,et al.  Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains , 2005, Nature Biotechnology.

[50]  R. Weissleder,et al.  Cell-specific targeting of nanoparticles by multivalent attachment of small molecules , 2005, Nature Biotechnology.

[51]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[52]  Peixuan Guo,et al.  Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. , 2005, Nano letters.

[53]  Kazunori Kataoka,et al.  Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. , 2005, Molecular bioSystems.

[54]  N. Lonberg.  Human antibodies from transgenic animals , 2005, Nature Biotechnology.

[55]  Qiang Zhang,et al.  Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. , 2005, Journal of pharmaceutical sciences.

[56]  A. Anagnostopoulos,et al.  The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia , 2005, Leukemia & lymphoma.

[57]  M. Amiji,et al.  Poly(ethylene oxide)-modified poly(ɛ-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer , 2005 .

[58]  M. Steiert,et al.  Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. , 2005, International journal of pharmaceutics.

[59]  R. Esenaliev,et al.  Enhancement of Drug Delivery in Tumors by Using Interaction of Nanoparticles with Ultrasound Radiation , 2005, Technology in cancer research & treatment.

[60]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[61]  Francis C Szoka,et al.  Biological evaluation of polyester dendrimer: poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture. , 2005, Molecular pharmaceutics.

[62]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[63]  M. Ferrari,et al.  A Theoretical Model for the Margination of Particles within Blood Vessels , 2005, Annals of Biomedical Engineering.

[64]  H. Ghandehari,et al.  Targeting tumor angiogenic vasculature using polymer-RGD conjugates. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[65]  E. K. Park,et al.  Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. , 2004, Biomaterials.

[66]  J. West,et al.  Metal Nanoshells , 2005, Annals of Biomedical Engineering.

[67]  Antonios G. Mikos,et al.  Review: Biodegradable Polymeric Scaffolds. Improvements in Bone Tissue Engineering through Controlled Drug Delivery , 2005 .

[68]  B. Sullenger,et al.  Aptamers: an emerging class of therapeutics. , 2005, Annual review of medicine.

[69]  K. Yarema,et al.  Targeting cancer cells with dendrimers. , 2005, Chemistry & biology.

[70]  J. Fréchet,et al.  Dendrimers and dendritic polymers in drug delivery. , 2005, Drug discovery today.

[71]  Omid C. Farokhzad,et al.  Nanoparticle-Aptamer Bioconjugates , 2004, Cancer Research.

[72]  J. Fréchet,et al.  Stimuli-responsive supramolecular assemblies of linear-dendritic copolymers. , 2004, Journal of the American Chemical Society.

[73]  N. Ueno,et al.  Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[74]  M. Gleave,et al.  Antisense approaches in prostate cancer , 2004, Expert opinion on biological therapy.

[75]  S. Deutscher,et al.  Is phage display technology on target for developing peptide-based cancer drugs? , 2004, Current drug discovery technologies.

[76]  Samuel Zalipsky,et al.  Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. , 2004, Advanced drug delivery reviews.

[77]  Serge Muyldermans,et al.  Efficient cancer therapy with a nanobody-based conjugate. , 2004, Cancer research.

[78]  R. Langer,et al.  Designing materials for biology and medicine , 2004, Nature.

[79]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[80]  Thommey P. Thomas,et al.  Design and Function of a Dendrimer-Based Therapeutic Nanodevice Targeted to Tumor Cells Through the Folate Receptor , 2002, Pharmaceutical Research.

[81]  J. Kopeček,et al.  The Role of Galactose, Lactose, and Galactose Valency in the Biorecognition of N-(2-Hydroxypropyl)Methacrylamide Copolymers by Human Colon Adenocarcinoma Cells , 2002, Pharmaceutical Research.

[82]  M. Alonso,et al.  Stealth PLA-PEG Nanoparticles as Protein Carriers for Nasal Administration , 1998, Pharmaceutical Research.

[83]  S. Simões,et al.  Sterically stabilized ph-sensitive liposomes. , 2004, Methods in enzymology.

[84]  P. McEuen,et al.  Controlled assembly of dendrimer-like DNA , 2004, Nature materials.

[85]  Samuel Zalipsky,et al.  In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  Robert Langer,et al.  Advances in Biomaterials, Drug Delivery, and Bionanotechnology , 2003 .

[87]  S. Kawakami,et al.  Targeted and sustained drug delivery using PEGylated galactosylated liposomes. , 2003, International journal of pharmaceutics.

[88]  R. Stafford,et al.  Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[89]  Robert Langer,et al.  Small-scale systems for in vivo drug delivery , 2003, Nature Biotechnology.

[90]  G. Whitesides.  The 'right' size in nanobiotechnology , 2003, Nature Biotechnology.

[91]  E. Kauppinen,et al.  Preparation of polymeric nanoparticles containing corticosteroid by a novel aerosol flow reactor method. , 2003, International journal of pharmaceutics.

[92]  K. Sakamoto,et al.  RNA interference and human disease. , 2003, Molecular genetics and metabolism.

[93]  R. Schiffelers,et al.  Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[94]  J. Verweij,et al.  Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours , 2003 .

[95]  A. Gabizon,et al.  Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. , 2003, Bioconjugate chemistry.

[96]  Christilyn P. Graff,et al.  Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. , 2003, Cancer research.

[97]  Elizabeth R Gillies,et al.  Designing macromolecules for therapeutic applications: polyester dendrimer-poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture. , 2002, Journal of the American Chemical Society.

[98]  Ulrik B Nielsen,et al.  Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. , 2002, Biochimica et biophysica acta.

[99]  Eugene S. Kim,et al.  Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[100]  D D Gibbs,et al.  A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer , 2002, British Journal of Cancer.

[101]  Francis C Szoka,et al.  Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. , 2002, Bioconjugate chemistry.

[102]  Ulrik B Nielsen,et al.  Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[103]  P. Low,et al.  Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. , 2002, Biochimica et biophysica acta.

[104]  S. Kane,et al.  LIPOSOMAL DAUNORUBICIN OVERCOMES DRUG RESISTANCE IN HUMAN BREAST, OVARIAN AND LUNG CARCINOMA CELLS , 2002, Journal of liposome research.

[105]  M. Linenberger,et al.  Mylotarg: antibody-targeted chemotherapy comes of age , 2001, Current opinion in oncology.

[106]  A. Bajo,et al.  Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness. , 2001, International journal of oncology.

[107]  D. Putnam,et al.  Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[108]  Robert Langer,et al.  Drugs on Target , 2001, Science.

[109]  R. Ho,et al.  Trends and developments in liposome drug delivery systems. , 2001, Journal of pharmaceutical sciences.

[110]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[111]  C. Heldin,et al.  Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. , 2001, Cancer research.

[112]  R. Jain.  Delivery of molecular and cellular medicine to solid tumors. , 2001, Advanced drug delivery reviews.

[113]  R Langer,et al.  Responsive polymeric delivery systems. , 2001, Advanced drug delivery reviews.

[114]  R Langer,et al.  Drug delivery. Drugs on target. , 2001, Science.

[115]  Louis M Weiner,et al.  New approaches to antibody therapy , 2000, Oncogene.

[116]  R. Müller,et al.  'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. , 2000, Colloids and surfaces. B, Biointerfaces.

[117]  M. Dewhirst,et al.  Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. , 2000, Cancer research.

[118]  K. Kono,et al.  Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[119]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[120]  P. Low,et al.  Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[121]  D. Patel,et al.  Adaptive recognition by nucleic acid aptamers. , 2000, Science.

[122]  A. Buzaid,et al.  Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. , 1999, Oncology reports.

[123]  M. Uhlén,et al.  An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein. , 1999, Immunotechnology : an international journal of immunological engineering.

[124]  D. Tzemach,et al.  Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. , 1999, Bioconjugate chemistry.

[125]  Leamon Cp,et al.  Folate-mediated drug delivery : Effect of alternative conjugation chemistry , 1999 .

[126]  R. Hendren,et al.  Folate-mediated drug delivery: effect of alternative conjugation chemistry. , 1999, Journal of drug targeting.

[127]  J. Szostak,et al.  In vitro selection of functional nucleic acids. , 1999, Annual review of biochemistry.

[128]  J W Szostak,et al.  Isolation and characterization of fluorophore-binding RNA aptamers. , 1998, Folding & design.

[129]  R. Langer,et al.  Drug delivery and targeting. , 1998, Nature.

[130]  P. Sado,et al.  Ophthalmic drug delivery systems—Recent advances , 1998, Progress in Retinal and Eye Research.

[131]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[132]  R. Jain,et al.  Delivery of molecular and cellular medicine to solid tumors. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[133]  Erkki Ruoslahti,et al.  αv Integrins as receptors for tumor targeting by circulating ligands , 1997, Nature Biotechnology.

[134]  R Langer,et al.  Characterization of glucose-mediated insulin release from implantable polymers. , 1996, Journal of pharmaceutical sciences.

[135]  C. S. Devine,et al.  A peptide isolated by phage display binds to ICAM‐1 and inhibits binding to LFA‐1 , 1996, Proteins.

[136]  E J Topol,et al.  Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. , 1996, Circulation.

[137]  Bernhard A. Sabel,et al.  Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections , 1996, Brain Research.

[138]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[139]  Y. Ikada,et al.  Tissue Reaction of Bioabsorbable Ultra High Strength Poly (L‐Lactide) Rod: A Long‐Term Study in Rabbits , 1995, Clinical orthopaedics and related research.

[140]  R. Lotan,et al.  Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. , 1995, Cancer research.

[141]  F. M. Huennekens,et al.  Methotrexate-alpha-phenylalanine: optimization of methotrexate prodrug for activation by carboxypeptidase A-monoclonal antibody conjugate. , 1995, Cancer research.

[142]  J. Ross,et al.  Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications , 1994, Cancer.

[143]  V. Torchilin,et al.  Biodegradable long-circulating polymeric nanospheres. , 1994, Science.

[144]  D Tomlinson,et al.  Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS. , 1994, Clinical oncology (Royal College of Radiologists (Great Britain)).

[145]  L R Coney,et al.  Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. , 1992, Cancer research.

[146]  A. Lefer,et al.  Endothelial alterations in hypercholesterolaemia and atherosclerosis. , 1991, Pharmacological research.

[147]  R Langer,et al.  New methods of drug delivery. , 1990, Science.

[148]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[149]  J. Scott,et al.  Searching for peptide ligands with an epitope library. , 1990, Science.

[150]  R. Jain,et al.  Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. , 1990, Cancer research.

[151]  N. Hogg,et al.  Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis , 1990, Nature.

[152]  R K Jain,et al.  Transport of molecules in the tumor interstitium: a review. , 1987, Cancer research.

[153]  B. Kamen,et al.  Receptor-mediated folate accumulation is regulated by the cellular folate content. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[154]  R. Langer,et al.  Polymers for the sustained release of proteins and other macromolecules , 1976, Nature.

[155]  A. Bangham,et al.  Diffusion of univalent ions across the lamellae of swollen phospholipids. , 1965, Journal of molecular biology.